Age of onset moderates the effects of Vascular Risk Factors on Neurodegeneration, Blood-Brain-Barrier permeability, and cognitive decline in Alzheimer’s Disease

Table 4 Demographics, clinical characteristics, and CSF dosages of patients included in the longitudinal cohort

	EOAD (n = 25)	cLOAD (n = 54)	vLOAD (n = 25)	p
Age (years)	59.16 ± 3.72	70.63 ± 3.08	77.88 ± 1.54	< 0.001***
Sex (%F)	40.00%	53.70%	68.00%	0.139
APOE (%ε4)	56.00%	57.41%	44.00%	0.479
ΔMMSE	−2.99 ± 3.73	−2.30 ± 2.59	−2.56 ± 1.84	0.589
p-tau/Aβ42	0.23 ± 0.14	0.24 ± 0.14	0.24 ± 0.12	0.890
t-tau (pg/ml)	635.09 ± 382.77	565.74 ± 310.64	602.46 ± 368.57	0.694
Qalb	8.20 ± 5.41	7.55 ± 4.48	6.47 ± 2.06	0.359
Vascular Score	0.185 ± 0.136	0.227 ± 0.188	0.260 ± 0.236	0.378

Legend. EOAD: early-onset AD (< 65 yo); cLOAD: classical onset AD (65–75 yo); vLOAD: late-onset AD (> 75 yo); F: female; APOE: Apolipoprotein E; ΔMMSE: one-year differences in Mini-Mental State Examination score; Qalb: albumin quotient; p: p-value. Bold values represent significativity ***= <0.001)

ISSN: 1758-9193